Around the world, health challenges are coupled with extreme poverty. Those who live in and experience extreme poverty are more likely to suffer from diseases and lack equipment to fend off and eradicate those diseases. However, organizations are working to provide vaccinations and medications globally to those in need. An excellent example of one such organization is Glasko Smith Kline — a group who fights poverty through global healthcare.
What is Glasko Smith Kline?
Glasko Smith Kline (GSK) is a “science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.” The company hopes to be innovative in their methods of healthcare by trying to reach as many people as possible. Glasko Smith Kline Fights Poverty through three areas of research and development in pharmaceutical medicines, vaccines and consumer healthcare products.
In the pharmaceutical arena, GSK is currently working on new medicines for HIV diseases and oncology. The organization has been a leader in respiratory disease for over forty years and has strengthened its repertoire of medications in recent years. GSK has an extensive portfolio for their vaccinations — they deliver two million vaccine doses per day to over 160 countries. Lastly, the consumer health care business focuses on oral health, pain relief, respiratory, nutrition and skin health. GSK leads in both over-the counter healthcare companies worldwide and rankings within the Wellness category in 36 markets.
GSK championed the effort to develop the first ever malaria vaccination, which took approximately thirty years to develop. Although preventative efforts have decreased the number of African children dying from malaria, vaccinations continue to decrease the mortality rate.
First Steps Towards Change
As of 2017, Ghana, Kenya and Malawi were set to begin the pilot vaccine with young children the following year. The World Health Organization’s (WHO) goal is to eradicate malaria by 2040, and as WHO works to implement these vaccines, GSK will eventually work to analyze the vaccine’s effectiveness and side effects. These findings will compliment the pilot evaluation data.
According to Access to Medicine Foundation’s index of drug companies, Glasko Smith Kline ranks first out of drug-making companies in its availability to developing companies. This nonprofit also reports that GSK’s major strength is research, and that its development projects are in need of further attention.
GSK and Save the Children
Glasko Smith Kline Fights Poverty in partnership with an organization called Save the Children. Save the Children advocates for children’s rights, basic needs and human rights. This organization works towards increased education, lower mortality rates and better health for the most vulnerable of human beings.
Save the Children recognizes that poverty is a common cause that effects a child’s future; therefore, the organization works to give a child a healthy start to life. The goal of the global partnership between GSK and Save the Children is to combine their expertise of global health and children rights to provide resources to save the lives of one million of the world’s poorest children.
Overall, Glasko Smith Kline Fights Poverty through multiple avenues. They utilize their strengths in consumer healthcare, vaccinations and medications, research breakthrough finds, and deliver these solutions to the people who are most in need. Also, by collaborating with other organizations, GSK is able to expand its reach to eradicate poverty through their passion for global healthcare.
– Jenna Walmer